The bill blocks the United States from becoming party to any World Health Organization (WHO) convention, agreement, or other instrument aimed at strengthening pandemic prevention, preparedness, and response unless that instrument is adopted as a treaty under Article II, section 2, clause 2 of the Constitution and receives Senate ratification. It ties U.S. participation to the formal treaty process rather than to executive agreements or other administrative commitments.
At the same time, the bill suspends U.S. obligations and expenditures for the WHO beginning on the effective date of any such WHO pandemic agreement and lasting until the Senate approves a resolution of ratification covering that instrument. The combined effect is to put the Senate’s treaty advice-and-consent power at the center of any future U.S. commitments to a WHO pandemic framework and to use funding leverage to enforce that requirement.
At a Glance
What It Does
The bill forbids the United States from becoming a party to WHO instruments on pandemic prevention, preparedness, or response except through a treaty made under the Constitution’s treaty clause and ratified by the Senate. It also prohibits federal agencies from obligating or spending funds for the WHO from the effective date of such an agreement until the Senate ratifies it.
Who It Affects
The executive branch — principally the Department of State, HHS, and agencies that fund or coordinate with WHO — the WHO itself, and countries and programs that depend on WHO cooperation and financing. The Senate gains a binding gatekeeping role over U.S. pandemic commitments.
Why It Matters
The bill replaces executive flexibility with a formal treaty requirement and ties U.S. funding to Senate action, creating a structural barrier to rapid U.S. participation in multilateral pandemic instruments. That changes how the United States can negotiate, execute, and fund future WHO pandemic arrangements.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Textually, the bill narrows the path by which the United States can assume international obligations under WHO on pandemic issues: only a treaty that the President concludes under Article II of the Constitution and that the Senate ratifies qualifies. That excludes executive agreements or administrative commitments the President might otherwise make without two‑thirds Senate consent.
The funding language is keyed to timing: when a qualifying WHO pandemic instrument becomes effective, U.S. agencies must stop obligating and spending funds for the WHO until the Senate approves a resolution of ratification for that specific instrument. The trigger is the instrument’s effective date rather than, for example, U.S. signature or U.S. accession, meaning a global agreement’s entry into force can automatically suspend U.S. financial support even if the United States has not joined it.Operationally, the bill imposes direct obligations on federal agencies: they cannot obligate or expend funds for WHO activities during the suspension period.
It does not create an explicit emergency exception or waiver process, nor does it set alternative funding mechanisms; the statutory bar simply remains until the Senate acts. Because the text confines itself to WHO instruments “to strengthen pandemic prevention, preparedness, and response,” its scope is focused but will require interpretive decisions about which WHO measures trigger the prohibition.Practically, this statute would change negotiation dynamics: foreign counterparts and the WHO would know that any binding pandemic architecture that becomes effective without prior Senate ratification risks cutting off U.S. funding.
That gives the Senate negotiating leverage but also risks sidelining the United States during multilateral rule‑making or operational responses that proceed under alternate legal forms.
The Five Things You Need to Know
The bill prohibits the United States from becoming a party to any WHO convention, agreement, or other instrument that strengthens pandemic prevention, preparedness, or response unless that instrument is concluded as a treaty under Article II, section 2, clause 2 and ratified by the Senate.
The statutory scope is explicit: it applies to instruments “under the Constitution of the World Health Organization” that address pandemic-related prevention, preparedness, and response.
On the effective date of any such WHO agreement, the United States must stop obligating or expending any funds for the WHO until the Senate approves a resolution of ratification with respect to that specific instrument.
The funding prohibition applies to the Government of the United States broadly — federal agencies may not obligate or expend funds for WHO activities during the suspension period.
The bill contains no built‑in emergency waiver or alternative funding authority; U.S. participation and WHO funding resume only after the Senate approves ratification.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the measure the “Defending American Sovereignty in Global Pandemics Act.” This is ceremonial but signals the bill’s intent to emphasize national decisionmaking over multilateral pandemic instruments.
Prohibition on assuming WHO pandemic obligations except by Senate‑ratified treaty
This subsection bars the United States from becoming a party to any WHO instrument aimed at pandemic prevention, preparedness, or response unless the United States joins that instrument via a treaty made under the Constitution’s treaty clause (Article II, section 2, clause 2). Constitutionally, that clause requires the President to secure the Senate’s advice and consent (historically a two‑thirds vote) for treaties. Functionally, the provision forecloses use of executive agreements or other non‑treaty mechanisms to accept binding obligations under relevant WHO instruments.
Suspension of U.S. funding for WHO tied to instrument’s effective date
This subsection prevents the U.S. government from obligating or expending any funds for the WHO beginning on the effective date of a qualifying WHO instrument and continuing until the Senate approves a resolution of ratification for that instrument. The trigger is the instrument’s effective date, not U.S. accession or signature, and the suspension ends only upon Senate ratification. The provision does not identify exceptions or alternative funding paths and therefore imposes a binary on‑or‑off funding rule linked to the Senate’s action.
This bill is one of many.
Codify tracks hundreds of bills on Foreign Affairs across all five countries.
Explore Foreign Affairs in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- U.S. Senate and individual Senators — the bill strengthens the Senate’s constitutional treaty role and gives Senators formal leverage over whether and when the United States binds itself to WHO pandemic instruments.
- Domestic actors skeptical of binding WHO authority — the measure creates a legal barrier to rapid transfer of decisionmaking power or obligations to the WHO without explicit Senate consent.
- Budget oversight advocates — by suspending obligations and expenditures automatically when an instrument becomes effective, the bill provides Congress a direct lever to control foreign entitlements and to compel review before funding resumes.
Who Bears the Cost
- World Health Organization — the bill conditions a major donor’s funding stream on Senate action and risks reduced or delayed U.S. contributions to WHO operations tied to pandemic instruments.
- U.S. executive branch agencies (Department of State, HHS, CDC) — the administration loses flexibility to negotiate or enter into non‑treaty arrangements and faces operational constraints in coordinating with WHO programs when a qualifying instrument takes effect.
- Countries and programs reliant on WHO funding, especially low‑ and middle‑income countries — suspension of U.S. funds could disrupt WHO‑led pandemic preparedness and response activities that depend on combined donor support.
- U.S. public health and research partnerships — ongoing collaborative projects administered through or supported by WHO may encounter funding gaps or legal uncertainty during suspension periods.
Key Issues
The Core Tension
The central dilemma is between preserving the Senate’s constitutional role to approve binding international commitments and maintaining the executive branch’s ability to secure rapid, effective multinational cooperation in a global health emergency; securing one diminishes the other, and the bill hard‑locks U.S. participation behind a slow, politically charged process even when speed can be decisive in pandemic response.
The bill raises immediate implementation questions. First, the phrase “become a party to a convention, agreement, or other international instrument under the Constitution of the World Health Organization” will require administrative and possibly judicial interpretation: WHO produces instruments in multiple legal forms (binding conventions, amendments, regulations, protocols, and non‑binding guidance) and the line between an instrument that “strengthens pandemic prevention” and ordinary WHO operations may be contested.
That interpretive ambiguity affects when the funding suspension would apply.
Second, the timing mechanism — tying the funding bar to the instrument’s effective date — can produce a perverse outcome: the United States could see its funding cut off by the entry into force of a WHO agreement that the U.S. has neither signed nor joined. That automatic suspension lever is powerful, but it risks degrading the WHO’s capacity to respond at precisely the moments when cooperation matters most.
The bill contains no emergency exception or targeted carve‑outs for lifesaving operations, and it does not address how pre‑existing obligations or multi‑year appropriations interact with the new prohibition.
Third, the statute advances the Senate’s treaty prerogative at the expense of executive flexibility, which may prompt separation‑of‑powers debates. Administratively, agencies will need clear guidance on interpreting the prohibition to avoid violating appropriations or the Antideficiency Act, and Congress may face pressure to supply implementing language in future appropriations bills.
Finally, the measure could incentivize multilateral actors to draft pandemic instruments in forms that avoid classification as a WHO instrument “under the Constitution” or to proceed with operational arrangements that are insulated from the statute’s reach, undermining the bill’s intended leverage.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.